Financials data is unavailable for this security.
View more
Year on year Katakura Industries Co Ltd grew revenues 16.62% from 34.27bn to 39.97bn while net income improved 8.13% from 2.82bn to 3.05bn.
| Gross margin | 38.62% |
|---|---|
| Net profit margin | 7.97% |
| Operating margin | 7.87% |
| Return on assets | 2.17% |
|---|---|
| Return on equity | 3.81% |
| Return on investment | 2.79% |
More ▼
Cash flow in JPYView more
In 2023, Katakura Industries Co Ltd did not generate a significant amount of cash. However, the company earned 3.83bn from its operations for a Cash Flow Margin of 9.58%. In addition the company generated 606.00m cash from investing, though they paid out 4.06bn more in financing than they received.
| Cash flow per share | 131.86 |
|---|---|
| Price/Cash flow per share | 16.59 |
| Book value per share | 2,357.16 |
|---|---|
| Tangible book value per share | 2,338.97 |
More ▼
Balance sheet in JPYView more
| Current ratio | 3.31 |
|---|---|
| Quick ratio | 2.56 |
| Total debt/total equity | 0.1345 |
|---|---|
| Total debt/total capital | 0.1026 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 25.00% and 8.25%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 0.94% |
|---|---|
| Div growth rate (5 year) | 10.76% |
| Payout ratio (TTM) | 22.92% |
| EPS growth(5 years) | 20.24 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -17.04 |
More ▼
